Anaplastic Large Cell Lymphoma, ALK-Negative
Associated Genetic Biomarkers
NCI Definition: A T-cell peripheral lymphoma morphologically indistinguishable from anaplastic large cell lymphoma, ALK-positive. It is characterized by the absence of the translocation involving the ALK gene and lacks expression of ALK fusion protein. 
Anaplastic large cell lymphoma, ALK-negatives most frequently harbor alterations in STAT3, JAK1, TP53, STAG2, and SOCS1 .
STAT3 Mutation, JAK1 Mutation, TP53 X307_splice, STAT3 Y640F, and STAT3 S614R are the most common alterations in anaplastic large cell lymphoma, ALK-negative .
There are 5 clinical trials for anaplastic large cell lymphoma, ALK-negative, of which 5 are open and 0 are completed or closed. Of the trials that contain anaplastic large cell lymphoma, ALK-negative as an inclusion criterion, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open).
ALK, CD7, and TNFRSF8 are the most frequent gene inclusion criteria for anaplastic large cell lymphoma, ALK-negative clinical trials .
Pembrolizumab, anti-cd7 car t-cells, and brentuximab vedotin are the most common interventions in anaplastic large cell lymphoma, ALK-negative clinical trials.
Significant Genes in Anaplastic Large Cell Lymphoma, ALK-Negative
ALK is an inclusion eligibility criterion in 1 clinical trial for anaplastic large cell lymphoma, ALK-negative, of which 1 is open and 0 are closed. Of the trial that contains ALK status and anaplastic large cell lymphoma, ALK-negative as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.